Nov 1, 2002
By:
Sarah Houlton
After saying last year that its treatments for AIDS and malaria were as cheap as they could be, GlaxoSmithKline now claims that improved manufacturing practices and greater economies of scale allow it to reduce prices even more.
|
UK Intellectual Property Rights Commission encourages developing countries to produce generic versions of vital medicines.
Nov 1, 2002
By:
Sarah Houlton
Patents help ensure that companies can recoup their development costs-and make profits-by selling their products without competition for a set period of time. The pharma industry has followed that model for decades.
|
Oct 1, 2002
By:
Sarah Houlton
Product development glitches continue to depress share prices at AstraZeneca. Poor trial results for the company's cancer drug Iressa followed hard on the heels of bad news about its cholesterol treatment Crestor (rosuvastatin).
|
Skittish investors and the need for large infusions of cash to see small biotechs through the early stage of drug development may drive a multimerger.
Oct 1, 2002
By:
Sarah Houlton
A major consolidation may be underway in the UK biotech sector. According to a report in London's Financial Times, several embattled companies specializing in cancer medicines are talking about a possible merger. Xenova, British Biotech, Antisoma, KS Biomedics, and Oxford GlycoSciences are believed to be in the early stages of discussions about merging to create a much stronger company.
|
Sep 1, 2002
By:
Sarah Houlton
Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance.
|
Sep 1, 2002
By:
Sarah Houlton
Many more high-risk patients could benefit from statin therapy than currently receive the cholesterol-lowering drugs, according to a major UK study set up by the Medical Research Council and the British Heart Foundation.
|
A movement is afoot to protect the intellectual property rights of indigenous people who have used plants as medicines for generations.
Sep 1, 2002
By:
Sarah Houlton
The number of pharmaceuticals derived from nature is staggering. Many medicine cabinet staples were first isolated from natural sources-penicillin from mold, quinine from the cinchona tree, digitalis (foxglove) for heart ailments, and the list goes on.
|
Sep 1, 2002
By:
Sarah Houlton
Shares in Danish company Novo Nordisk took a hit after it suspended trials for one of its main pipeline candidates, the dual-acting insulin sensitizer, ragaglitazar.
|
Sep 1, 2002
By:
Sarah Houlton
Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
